Adial pharmaceuticals, inc. (ADIL)
Income statement / Yearly
Dec'19Dec'18Dec'17
Operating Expenses:
Research and development expenses

3,965

368

182

General and administrative expenses

4,279

6,618

813

Total Operating Expenses

8,244

6,987

995

Loss From Operations

-8,244

-6,987

-995

Other Income (Expense)
Interest income

95

7

0

Loss on debt extinguishments

-

-3,484

-

Warrant modification expense

-441

-

-

Interest and financing charges

-

1,167

144

Total other income (expense)

-346

-4,644

-144

Loss Before Provision For Income Taxes

-8,591

-11,631

-1,139

Net Loss

-8,591

-11,631

-1,139

Net loss per share, basic and diluted

-0.87

-2.44

-0.35

Weighted average shares, basic and diluted

9,852

4,759

3,264